BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32001260)

  • 21. Nuclear TIGAR mediates an epigenetic and metabolic autoregulatory loop
    Wang H; Wang Q; Cai G; Duan Z; Nugent Z; Huang J; Zheng J; Borowsky AD; Li JJ; Liu P; Kung HJ; Murphy L; Chen HW; Wang J
    Acta Pharm Sin B; 2022 Apr; 12(4):1871-1884. PubMed ID: 35847493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
    Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
    FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
    Park JW; Kang JY; Hahm JY; Kim HJ; Seo SB
    Commun Biol; 2020 Aug; 3(1):462. PubMed ID: 32826945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in Chondrosarcomas.
    Aury-Landas J; Girard N; Lhuissier E; Adouane D; Delépée R; Boumediene K; Baugé C
    Cell Physiol Biochem; 2019; 53(4):731-745. PubMed ID: 31613064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NSD2 is downregulated in T2DM and promotes β cell proliferation and insulin secretion through the transcriptionally regulation of PDX1.
    Shi S; Zhao L; Zheng L
    Mol Med Rep; 2018 Sep; 18(3):3513-3520. PubMed ID: 30066931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.
    Tanaka H; Igata T; Etoh K; Koga T; Takebayashi SI; Nakao M
    Aging Cell; 2020 Jul; 19(7):e13173. PubMed ID: 32573059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
    Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
    Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
    Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
    Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
    Shen L; Cui J; Pang YX; Ma YH; Liu PS
    Asian Pac J Cancer Prev; 2013; 14(5):2915-8. PubMed ID: 23803053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Scalable Platform for Producing Recombinant Nucleosomes with Codified Histone Methyltransferase Substrate Preferences.
    McDevitt PJ; Schneck JL; Diaz E; Hou W; Huddleston MJ; Matico RE; McCormick PM; Kirkpatrick RB
    Protein Expr Purif; 2019 Dec; 164():105455. PubMed ID: 31306746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
    Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
    Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NSD2 methylates AROS to promote SIRT1 activation and regulates fatty acid metabolism-mediated cancer radiotherapy.
    Li X; Song D; Chen Y; Huang C; Liu A; Wu Q; She X; Li K; Wan K; Yu C; Qiu C; Liu L; Wang G; Xu F; Wang J; Hu J
    Cell Rep; 2023 Oct; 42(10):113126. PubMed ID: 37756162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.
    Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
    Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction of histone modification related H3F3B and NSD2 genes increases the susceptibility to schizophrenia in a Chinese population.
    Liu W; Fang Y; Shi Y; Cheng Y; Sun C; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jul; 101():109918. PubMed ID: 32169559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.
    Chong PSY; Chooi JY; Lim JSL; Leow ACY; Toh SHM; Azaman I; Koh MY; Teoh PJ; Tan TZ; Chung TH; Chng WJ
    Cancer Res; 2023 Oct; 83(20):3414-3427. PubMed ID: 37463241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.